ImClone appoints former J&J exec as CEO

Share this article:

ImClone Systems said Thursday that former Johnson & Johnson executive John Johnson will take over as CEO effective Aug. 27.

Johnson most recently served as group chairman of J&J's worldwide biopharmaceuticals unit and has held various senior management positions at J&J.

ImClone had previously been run by a committee created when investor Carl Icahn took over the company and ousted its top officials 10 months ago. 
 
Johnson has a challenging job ahead as ImClone looks to expand its pipeline and the market for its only product Erbitux, currently approved for use to treat cancers of the head and neck and colorectal cancers.

ImClone and marketing partner Bristol Myers-Squibb had hoped to win approval for Erbitux as a lung cancer treatment however a recent late-stage study of the drug in lung-cancer patients didn't meet the primary endpoint of progression-free survival.

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.